Zelboraf (vemurafenib) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration. Deprecated

Citation

Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf. Revised November 2017. Accessed October 6, 2026.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
ZELBORAF is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation. 2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (1) BRAF p.V600E Erdheim-Chester Disease Vemurafenib
FDA (1) BRAF p.V600K Erdheim-Chester Disease Vemurafenib